SUN06 Innovations in Blistering Diseases
DESCRIPTION
There are an increasing number of new diagnostic modalities and management options available for autoimmune blistering disorders. In this session, we will discuss the current evidence-based diagnostic and treatment options for autoimmune mucocutaneous blistering disorders. In addition, we will review cases and update clinicians on appropriate management strategies.
LEARNING OBJECTIVES
Discuss the pathogenesis of blistering disorders and review current management options for immunobullous disorders
Recognize the impact of skin of color on bullous dermatoses
Provide a real world perspective of management of AIBD in the hospital and outpatient setting
SCHEDULE
2:30 PM
Emerging Therapies in Pemphigus
Cory Simpson, MD, PhD, FAAD
2:41 PM
Bullous Pemphigoid Updates
Prince Adotama, MD, FAAD
2:52 PM
Overview of Immunotherapies AIBDs and Management
Brittney Schultz, MD, FAAD
3:03 PM
Pediatric Bullous Disorders
Thy Nhat Huynh, MD, FAAD
3:14 PM
Inpatient management of Bullous Disorders
Benedict Wu, DO, PhD, FAAD
3:25 PM
Questions and Answers
SPEAKERS
Prince Adotama, MD, FAAD
Thy Nhat Huynh, MD, FAAD
Brittney Schultz, MD, FAAD
Cory Simpson, MD, PhD, FAAD
Department of Dermatology, University of Washington
Benedict Wu, DO, PhD, FAAD
Montefiore Einstein/Albert Einstein College of Medicine
HANDOUTS
SPEAKER DISCLOSURES
Prince Adotama, MD, FAAD
arGEN-X – Advisory Board(Honoraria); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria); Catalyst Medical Education LLC – Speaker(Honoraria); Galderma – Consultant (1099 relationship)(Honoraria); Janssen Scientific Affairs, LLC – Advisory Board(Honoraria); Procter & Gamble Company – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Thy Nhat Huynh, MD, FAAD
No financial relationships exist with ineligible companies.
Brittney Schultz, MD, FAAD
arGEN-X – Advisory Board(Honoraria); AstraZeneca – Investigator(No Compensation Received); Elorac, Inc. – Investigator(No Compensation Received); UCB – Investigator(No Compensation Received);
Cory Simpson, MD, PhD, FAAD
argenx – Advisory Board(Fees); LEO Foundation – Investigator(Grants/Research Funding); Mitsubishi Tanabe Pharma Development America – Advisory Board(Fees); United Health Care – Employee(Salary), Employee(Stock Options);
Benedict Wu, DO, PhD, FAAD
argenx – Advisory Board(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria);